Characteristics and Methods Used For Developing the 11 Clinical Practice Guidelines.

<p>NR: Not reported. SOA: South Africa; IND: India; POL: Poland; MAL: Malaysia; EUR: Europe; JAP: Japan; LAT: Latin America; AUS: Australia; CAN: Canada, SAU: Saudi Arabia and NICE (The UK's National Institute for Health and Clinical Excellence).</p>*<p>The ESH Reappraisal in 2009 cited only 1 review (4 reviews were cited in 2007).</p>**<p>Produced by the Hypertension Cochrane Review Group calculated for up to one year before the date of publication of the CPGs when the search date was not reported.</p>***<p>The total number of reviews available at that time was 41 but two reviews were excluded because they were judged as irrelevant.</p>****<p>The updated version of Murlow's review was published in 2008 but the 2000 version was the one cited.</p

Recommendations from Clinical Practice Guidelines About Diagnosis and Assessment of Patients with Hypertension.

<p>NR: Not reported, √: Recommended, ×: Not Recommended; SOA: South Africa; IND: India; POL: Poland; MAL: Malaysia; EUR: Europe; JAP: Japan; LAT: Latin America; AUS: Australia; CAN: Canada; SAU: Saudi Arabia and NICE (The UK's National Institute for Health and Clinical Excellence).</p>$<p>not endorsed by NICE. ABI: ankle-brachial index ECD: Echo Carotid Doppler, RAU: Renal artery duplex ultrasound.</p

Quality of the 11 Hypertension Clinical Practice Guidelines for the six domains of the AGREE-II Instrument (D1–D6) and the Overall Impression of the 4 Assessors.

<p>D1 : Scope & purpose, D2: Stakeholder involvement, D3: Rigor of involvement, D4: Clarity of presentation, D5: Applicability, D6: editorial independence.</p><p>All the 23 items of the AGREE-II instrument are rated on a 7-point scale where a score of 1 is given when there is no information that is relevant to the item or if the concept is very poorly reported; a score of 7 is given if the quality of reporting is exceptional and where the full criteria and considerations articulated in the AGREE-II User's Manual have been met; and a score between 2 and 6 is assigned when the reporting of the AGREE II item does not meet the full criteria or considerations. Scores increase as more criteria are met and considerations addressed. In other words, the higher the score, the better the quality of the CPG item.</p><p>SOA: South Africa; IND: India; POL: Poland; MAL: Malaysia; EUR: Europe; JAP: Japan; LAT: Latin America; AUS: Australia; CAN: Canada; SAU: Saudi Arabia and NICE: UK's National Institute for Health and Clinical Excellence).</p>*<p>Although the scoring is done in integers, the numbers in this column represent the averages of the scoring done by 4 assessors.</p>**<p>Risk of bias: +++ high, ++ intermediate, + low.</p>***<p>This is based on the subjective assessment made individually by each of the 4 assessors in response to: “Do you recommend this CPG for use?”</p

Domain Scores (%) for the 11 Clinical Practice Guidelines Using the AGREE-II Instrument.

<p>SOA: South Africa; IND: India; POL: Poland; MAL: Malaysia; EUR: Europe; JAP: Japan; LAT: Latin America; AUS: Australia; CAN: Canada; SAU: Saudi Arabia and NICE: UK's National Institute for Health and Clinical Excellence.</p

Recommendations from Clinical Practice Guidelines about Managing Patients with Hypertension.

<p>SOA: South Africa; IND: India; POL: Poland; MAL: Malaysia; EUR: Europe; JAP: Japan; LAT: Latin America; AUS: Australia; CAN: Canada and SAU: Saudi Arabia and NICE (The UK's National Institute for Health and Clinical Excellence). NR: not reported. A: angiotensin converting enzyme inhibitor (ACEI), or angiotensin receptor blockers (ARB), C: calcium channel blocker (CCB), D: Diuretic.</p>1<p>And if SBP>150 and or DBP>95- treat.</p>2<p>If the SBP> or  = 140 mm Hg or DBP> or  = 90 mm Hg across 5 visits.</p>3<p>if SBP = 120–159 mmHg AND/OR DBP = 80–99 mmHg.</p>4<p>If, at visit 2 within one month, SBP is > or  = 140 mm Hg and/or DBP is > or  = 90 mm Hg.</p>5<p>If SBP = 120–159 mmHg AND/OR DBP = 80–99 mmHg with high risk or if SBP 160 mmHg AND/OR DBP 100 mmHg regardless of risk.</p>6<p>NICE CPG favored A for those below 55 years and C, D, for those aged 55 years or older and for black patients.</p>7<p>Yes if SBP>10 mmHg above target.</p>8<p>Recommended in at least certain high risk groups.</p>9<p>Recommended for those with atherosclerotic renal artery stenosis only.</p>10<p>No target level stated.</p>11<p>A1c<6.5 mmol/L.</p>12<p>A1c between 6.5–7% in patients with HTN, DM and nephropathy.</p>13<p>Referred to previous guideline version.</p>14<p>Every 3–6 months;</p>15<p>Every 3 months for high risk patients and every 6 months for low risk patients;</p>16<p>Every 3 months for the first year then 6-monthly thereafter;</p>17<p>Once a year.</p>18<p>For pheochromocytoma cases only.</p

Flow chart using the PRISMA statement for the systematic review.

<p>Flow chart using the PRISMA statement for the systematic review.</p